Alkermes Invests In Novel CNS Targets With Rodin Acquisition
Rodin is developing HDAC CoREST complex inhibitors for neurological conditions, with a lead candidate having completed Phase I testing. Alkermes will pay $100m upfront.
You may also be interested in...
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.